ICSR Processing in Pharmacovigilance: Step-by-Step Workflow

 ICSR Processing in Pharmacovigilance: Step-by-Step Workflow for Beginners

Introduction

Pharmacovigilance focuses on the continuous monitoring of medicine safety in real-world use. One of the core activities in this field is the processing of Individual Case Safety Reports (ICSRs). An ICSR contains information about a suspected adverse drug reaction reported by a patient, healthcare professional, or other credible source, and it helps identify potential safety concerns related to medicinal products.

ICSR processing involves a sequence of clearly defined steps, starting from the receipt of a case and continuing through data verification, medical assessment, regulatory reporting, and follow-up. Each step must be completed accurately and within regulatory timelines to ensure compliance and to support patient safety.

In this blog, the ICSR processing workflow is explained in a step-by-step manner, highlighting how safety cases are handled in routine pharmacovigilance practice. This guide is designed to provide a practical understanding of the process and is particularly useful for individuals new to pharmacovigilance or preparing for roles in drug safety and regulatory affairs.

If you are new to pharmacovigilance terminology, read our guide on Key Terminologies in Pharmacovigilance Explained.

Individual Case Safety Report(ICSR) Processing:

An Individual Case Safety Report (ICSR) is an official pharmacovigilance document used to record and evaluate a suspected adverse drug reaction in an individual patient, helping to monitor the safety of medicinal products.

A valid ICSR must contain a four minimum criteria. Learn more in our article on Adverse Drug Reactions (ADR): Types, Minimum Criteria and Challenge-Dechallenge-Rechallenge.

1. Case Intake:

• Case intake is the first step in ICSR processing. 
• It involves collecting adverse event case information from various sources, including healthcare professionals, patients, clinical studies, literature reports, regulatory authorities, and spontaneous reports. 
• After a case is received, it is reviewed to check for duplication. 
• If the case is identified as a duplicate, it is either nullified or removed from the database.
• If the case is confirmed to be new, a unique case identification number is assigned, and the case is forwarded for further processing.

2. Triage:

Triage is the process of validating a case against the minimum case validity criteria and categorizing it as a serious case, non-serious case, or no case/invalid case.  

• A serious case is one that meets at least one seriousness criterion.
• A non-serious case does not meet any seriousness criteria. 
• A no case or invalid case is one that does not meet the minimum validity requirements or has missing mandatory information.

3. Data Entry:

Data entry is the step where validated case information from the triage process is recorded into the pharmacovigilance database. 

All essential details—including the 

• Adverse event, 
• Patient information, 
• Suspected drug(s), 
• Reporter information, and
•  any supporting documents—are entered accurately.

This step ensures that the case is organized according to regulatory standards (such as ICH E2B) and is prepared for further processing, coding, and submission. 
Accuracy during data entry is critical, as mistakes can affect case evaluation, signal detection, and regulatory reporting.

4. Medical Coding:

Medical Coding is the process of assigning standardized codes to all terminologies used in case information, including diseases, drugs, adverse events, and medical conditions, according to country-specific regulated medical dictionaries. 

This ensures consistency, accuracy, and regulatory compliance in pharmacovigilance.

Examples of coding dictionaries and full forms:

• Diseases: ICD-10 (International Classification of Diseases, 10th Revision), ICD-11 (International Classification of Diseases, 11th Revision)

• Drugs: WHO-DD (World Health Organization Drug Dictionary), 

                          DRL (Drug Regulatory List)

• Adverse Events: WHO-ART (World Health Organization Adverse Reaction Terminology), 

• FDA-COSTART (Food and Drug Administration Coding Symbols for a Thesaurus of Adverse Reaction Terms, now replaced by 

• MedDRA – Medical Dictionary for Regulatory Activities)

Medical coding is essential for standardizing case data, facilitating accurate signal detection, analysis, and reporting to regulatory authorities.

To understand medical coding with examples, read our article on Medical Coding in Pharmacovigilance (MedDRA Explained with Practice Cases).

5. Causality Assessment:

It is the process of evaluating whether a reported adverse event is related to the suspected drug. 

It helps determine the likelihood of a causal relationship and supports regulatory reporting and patient safety decisions. 

Causality assessment can be performed using standardized tools such as the 

• WHO-UMC (World Health Organization – Uppsala Monitoring Centre) scale 
• Naranjo algorithm

which provides structured criteria to classify the likelihood of a drug-event relationship.

• Read our detailed guide on Causality Assessment in Pharmacovigilance to understand how drug-event relationships are evaluated.

6. Narrative Writing:

• Narrative writing is the process of summarizing the case findings after completion of ICSR processing. 
• The narrative is written in a clear chronological order and includes all relevant information related to the patient, suspected drug(s), adverse event(s), clinical course, treatment provided, and outcome, presented in a structured narrative format.
• A well-written narrative enables reviewers and regulatory authorities to clearly understand what happened, when it occurred, and how the event progressed, making it a critical component of safety case evaluation and regulatory submission.
• For a detailed explanation, read our guide on Pharmacovigilance Narrative Writing: Guidelines and Standard Structure.

7. Quality assessment:

• It is the step in ICSR processing where the completed case is reviewed for accuracy, completeness, and compliance with regulatory and internal quality standards. 
• It verifies that all components, including data entry, medical coding, causality assessment, and narrative writing, are consistent and correct.
• This step helps identify and resolve errors or missing information before regulatory submission, ensuring reliable safety evaluation and compliant reportin

8. Medical Expert Review:

• Medical expert review is the stage in ICSR processing in which a medically qualified professional assesses the case for clinical accuracy and sound medical judgment. 
• The review includes evaluation of the adverse event description, assessment of seriousness, review of causality, and confirmation of the overall clinical relevance of the reported information.

9. Regulatory submission:

It is the step in ICSR processing where a reviewed safety case is reported to health authorities within the required timelines. This ensures regulatory compliance and helps authorities continuously monitor the safety of medicines.

Regulatory Reporting Timelines:

• Serious Adverse Event (SAE): Reported in accordance with local regulatory requirements, generally within 15 calendar days.
• SUSAR (Suspected Unexpected Serious Adverse Reaction): Fatal or life-threatening SUSAR: submitted within 7 calendar days, with follow-up information provided within the next 8 days.
• Non-fatal SUSAR: submitted within 15 calendar days.
• Non-Serious Adverse Event: Not subject to expedited reporting and typically included in periodic safety reports, such as PSUR (Periodic Safety Update Report) or PBRER (Periodic Benefit-Risk Evaluation Report).

10. Signal Detection:

Signal detection is the process of identifying and evaluating potential safety concerns related to a medicinal product by reviewing and analyzing adverse event data. It involves recognizing patterns or trends that may suggest a possible causal relationship between a drug and an adverse event. 

Learn more about signal detection methods in our article on Signal Detection in Pharmacovigilance: Concepts, Methods and Examples.

11. Follow-Up and Case Closure:

Follow-up is an important step in ICSR processing, especially when the initial case information is incomplete or unclear. Additional details may be requested from the reporter, healthcare professional, or other sources to obtain missing or clarifying information related to the adverse event, patient history, treatment, or outcome.

Frequently Asked Questions (FAQs)

1. What is an ICSR in pharmacovigilance?

An Individual Case Safety Report (ICSR) is a structured report describing a suspected adverse drug reaction experienced by a patient.

2. What are the four minimum criteria for a valid ICSR?

A valid ICSR requires:

1. Identifiable patient

2. Identifiable reporter

3. Suspected drug

4. Suspected adverse event

3. Why is ICSR processing important?

ICSR processing helps detect drug safety signals and ensures regulatory authorities receive accurate safety information.

Conclusion:

ICSR processing is a structured and essential workflow in pharmacovigilance that ensures the accurate collection, evaluation, and reporting of adverse drug reactions. Each step—from case intake and triage to regulatory submission and signal detectionplays a vital role in ensuring patient safety and regulatory compliance.